메뉴 건너뛰기




Volumn 7, Issue 6, 2008, Pages 761-769

Olanzapine: Review of safety 2008

Author keywords

Antipsychotic side effects; Antipsychotic induced weight gain; Effectiveness; Olanzapine

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; CLOZAPINE; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SULPIRIDE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

EID: 57049123316     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802423234     Document Type: Review
Times cited : (58)

References (97)
  • 1
    • 57049146698 scopus 로고    scopus 로고
    • Available from:, Last accessed 2008 May 21
    • Zyprexa. Anon. 2008. Available from: http://pi.lilly.com/us/ zyprexa-pi.pdf [Last accessed 2008 May 21]
    • (2008)
  • 2
    • 0023254675 scopus 로고
    • Dopamine receptors and the dopamine hypothesis of schizophrenia
    • Seeman P. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1987;1(2):133-52
    • (1987) Synapse , vol.1 , Issue.2 , pp. 133-152
    • Seeman, P.1
  • 3
    • 0036221550 scopus 로고    scopus 로고
    • Atypical antipsychotics: Mechanism of action
    • Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002;47(1):27-38
    • (2002) Can J Psychiatry , vol.47 , Issue.1 , pp. 27-38
    • Seeman, P.1
  • 4
    • 0003841783 scopus 로고    scopus 로고
    • 3rd edition. Cambridge, UK: Cambridge University Press;
    • Stahl SM. Stahl's Essential Psychopharmacology. 3rd edition. Cambridge, UK: Cambridge University Press; 2008
    • (2008) Essential Psychopharmacology
    • Stahl's, S.S.M.1
  • 5
    • 33644684681 scopus 로고    scopus 로고
    • Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus
    • Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20(5):368-78
    • (2005) Drug Metab Pharmacokinet , vol.20 , Issue.5 , pp. 368-378
    • Matsui-Sakata, A.1    Ohtani, H.2    Sawada, Y.3
  • 6
    • 23144441853 scopus 로고    scopus 로고
    • The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment
    • Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(6):1021-8
    • (2005) Prog Neuropsychopharmacol Biol Psychiatry , vol.29 , Issue.6 , pp. 1021-1028
    • Reynolds, G.P.1    Templeman, L.A.2    Zhang, Z.J.3
  • 7
    • 38349190623 scopus 로고    scopus 로고
    • Sex, race, and smoking impact olanzapine exposure
    • Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008;48(2):157-65
    • (2008) J Clin Pharmacol , vol.48 , Issue.2 , pp. 157-165
    • Bigos, K.L.1    Pollock, B.G.2    Coley, K.C.3
  • 8
    • 45249085941 scopus 로고    scopus 로고
    • An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia
    • Lauriello J, Lambert T, Andersen S, et al. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry 2008;69(5):790-9
    • (2008) J Clin Psychiatry , vol.69 , Issue.5 , pp. 790-799
    • Lauriello, J.1    Lambert, T.2    Andersen, S.3
  • 9
    • 57049114182 scopus 로고    scopus 로고
    • Briefing Document for Olanzapine Pamoate (OP) Depot.United States Food and Drug Administration Pharmacological Drugs Advisory Committee. 2008 February 6. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/08/ briefing/2008-4338bl-03-Lilly.pdf [Last accessed 2008 June 8]
    • Briefing Document for Olanzapine Pamoate (OP) Depot.United States Food and Drug Administration Pharmacological Drugs Advisory Committee. 2008 February 6. Available from: http://www.fda.gov/OHRMS/DOCKETS/AC/08/ briefing/2008-4338bl-03-Lilly.pdf [Last accessed 2008 June 8]
  • 10
    • 36949008116 scopus 로고    scopus 로고
    • D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: An open-label study in patients with schizophrenia
    • Mamo D, Kapur S, Keshavan M, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology 2008;33(2):298-304
    • (2008) Neuropsychopharmacology , vol.33 , Issue.2 , pp. 298-304
    • Mamo, D.1    Kapur, S.2    Keshavan, M.3
  • 11
    • 0038653525 scopus 로고    scopus 로고
    • A meta-analysis of the efficacy of second-generation antipsychotics
    • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64
    • (2003) Arch Gen Psychiatry , vol.60 , Issue.6 , pp. 553-564
    • Davis, J.M.1    Chen, N.2    Glick, I.D.3
  • 12
    • 25144456112 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia
    • Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
    • (2005) N Engl J Med , vol.353 , Issue.12 , pp. 1209-1223
    • Lieberman, J.A.1    Stroup, T.S.2    McEvoy, J.P.3
  • 13
    • 40949142200 scopus 로고    scopus 로고
    • Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial
    • Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085-97
    • (2008) Lancet , vol.371 , Issue.9618 , pp. 1085-1097
    • Kahn, R.S.1    Fleischhacker, W.W.2    Boter, H.3
  • 14
    • 33749321169 scopus 로고    scopus 로고
    • Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
    • Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch of Gen Psychiatry 2006;63(10):1079-87
    • (2006) Arch of Gen Psychiatry , vol.63 , Issue.10 , pp. 1079-1087
    • Jones, P.B.1    Barnes, T.R.2    Davies, L.3
  • 15
    • 38049002952 scopus 로고    scopus 로고
    • Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: A quantitative review of efficacy and safety
    • Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68(12):1876-85
    • (2007) J Clin Psychiatry , vol.68 , Issue.12 , pp. 1876-1885
    • Citrome, L.1
  • 16
    • 15944379171 scopus 로고    scopus 로고
    • Toward convergence in the medication treatment of bipolar disorder and schizophrenia
    • Citrome L, Goldberg JF, Stahl SM. Toward convergence in the medication treatment of bipolar disorder and schizophrenia. Harv Rev Psychiatry 2005;13(1):28-42
    • (2005) Harv Rev Psychiatry , vol.13 , Issue.1 , pp. 28-42
    • Citrome, L.1    Goldberg, J.F.2    Stahl, S.M.3
  • 17
    • 0032919745 scopus 로고    scopus 로고
    • Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Study Group
    • Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania: Olanzapine HGEH Study Group. Am J Psychiatry 1999;156(5):702-9
    • (1999) Am J Psychiatry , vol.156 , Issue.5 , pp. 702-709
    • Tohen, M.1    Sanger, T.M.2    McElroy, S.L.3
  • 18
    • 0033863937 scopus 로고    scopus 로고
    • Efficacy of olanzapine in acute bipolar mania: A double-blind, placebo-controlled study. The Olanzipine HGGW Study Group
    • Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry 2000;57(9):841-9
    • (2000) Arch Gen Psychiatry , vol.57 , Issue.9 , pp. 841-849
    • Tohen, M.1    Jacobs, T.G.2    Grundy, S.L.3
  • 19
    • 0041977102 scopus 로고    scopus 로고
    • Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study
    • Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry 2003;160(7):1263-71
    • (2003) Am J Psychiatry , vol.160 , Issue.7 , pp. 1263-1271
    • Tohen, M.1    Ketter, T.A.2    Zarate, C.A.3
  • 20
    • 10744220918 scopus 로고    scopus 로고
    • Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression
    • Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60(11):1079-88
    • (2003) Arch Gen Psychiatry , vol.60 , Issue.11 , pp. 1079-1088
    • Tohen, M.1    Vieta, E.2    Calabrese, J.3
  • 21
    • 33747169047 scopus 로고    scopus 로고
    • A 7-week, randomized, double-blind trial of olanzapine/fluoxerine combination versus lamotrigine in the treatment of bipolar I depression
    • Brown EB, McElroy SL, Keck PEJ, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxerine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2003;67(7):1025-33
    • (2003) J Clin Psychiatry , vol.67 , Issue.7 , pp. 1025-1033
    • Brown, E.B.1    McElroy, S.L.2    Keck, P.E.J.3
  • 22
    • 0032751075 scopus 로고    scopus 로고
    • Antipsychotic-induced weight gain: A comprehensive research synthesis
    • Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156(11):1686-96
    • (1999) Am J Psychiatry , vol.156 , Issue.11 , pp. 1686-1696
    • Allison, D.B.1    Mentore, J.L.2    Heo, M.3
  • 23
    • 0036936014 scopus 로고    scopus 로고
    • A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder
    • Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry 2002;63(12):1148-55
    • (2002) J Clin Psychiatry , vol.63 , Issue.12 , pp. 1148-1155
    • Zajecka, J.M.1    Weisler, R.2    Sachs, G.3
  • 24
    • 0036274760 scopus 로고    scopus 로고
    • Olanzapine versus divalproex in the treatment of acute mania
    • Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry 2002;159(6):1011-7
    • (2002) Am J Psychiatry , vol.159 , Issue.6 , pp. 1011-1017
    • Tohen, M.1    Baker, R.W.2    Altshuler, L.L.3
  • 25
    • 10744221700 scopus 로고    scopus 로고
    • A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania
    • Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60(12):1218-26
    • (2003) Arch Gen Psychiatry , vol.60 , Issue.12 , pp. 1218-1226
    • Tohen, M.1    Goldberg, J.F.2    Gonzalez-Pinto Arrillaga, A.M.3
  • 26
    • 33845636133 scopus 로고    scopus 로고
    • Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: A randomized, double-blind trial
    • Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed States in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry 2006;67(11):1747-53
    • (2006) J Clin Psychiatry , vol.67 , Issue.11 , pp. 1747-1753
    • Perlis, R.H.1    Baker, R.W.2    Zarate Jr, C.A.3
  • 27
    • 26444456116 scopus 로고    scopus 로고
    • Olanzapine versus ziprasidone: Results of a 28-week double-blind study in patients with schizophrenia
    • Breier A, Berg PH, Thakore JH, et al. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162(10):1879-87
    • (2005) Am J Psychiatry , vol.162 , Issue.10 , pp. 1879-1887
    • Breier, A.1    Berg, P.H.2    Thakore, J.H.3
  • 28
    • 33750614310 scopus 로고    scopus 로고
    • Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: A 52-week, open-label comparison with olanzapine
    • Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189(2):259-66
    • (2006) Psychopharmacology , vol.189 , Issue.2 , pp. 259-266
    • Chrzanowski, W.K.1    Marcus, R.N.2    Torbeyns, A.3
  • 29
    • 33747398701 scopus 로고    scopus 로고
    • Olanzapine and haloperidol in first episode psychosis: Two-year data
    • Green AI, Lieberman JA, Hamer RM, et al. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res 2006;86(1-3):234-43
    • (2006) Schizophr Res , vol.86 , Issue.1-3 , pp. 234-243
    • Green, A.I.1    Lieberman, J.A.2    Hamer, R.M.3
  • 30
    • 33748743350 scopus 로고    scopus 로고
    • Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning
    • Kinon BJ, Noordsy DL, Liu-Seifert H, et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006;26(5):453-61
    • (2006) J Clin Psychopharmacol , vol.26 , Issue.5 , pp. 453-461
    • Kinon, B.J.1    Noordsy, D.L.2    Liu-Seifert, H.3
  • 31
    • 33746885198 scopus 로고    scopus 로고
    • Comparison of atypicals in first-episode psychosis: A randomized, 52-week comparison of olanzapine, quetiapine, and risperidone [abstract no. P.3.163]
    • Lieberman JA, McEvoy JP, Perkins DO, et al. Comparison of atypicals in first-episode psychosis: A randomized, 52-week comparison of olanzapine, quetiapine, and risperidone [abstract no. P.3.163]. Eur Neuropsychopharmacol 2005;15(3 Suppl):S526
    • (2005) Eur Neuropsychopharmacol , vol.15 , Issue.3 SUPPL.
    • Lieberman, J.A.1    McEvoy, J.P.2    Perkins, D.O.3
  • 32
    • 16644402581 scopus 로고    scopus 로고
    • A comparison of weight change during treatment with olanzapine or aripiprazole: Results from a randomized, double-blind study
    • McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(18 Suppl):47-56
    • (2004) J Clin Psychiatry , vol.65 , Issue.18 SUPPL. , pp. 47-56
    • McQuade, R.D.1    Stock, E.2    Marcus, R.3
  • 33
    • 34147185609 scopus 로고    scopus 로고
    • Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine
    • Peuskens J, De Hert M, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol 2007;22(3):145-52
    • (2007) Int Clin Psychopharmacol , vol.22 , Issue.3 , pp. 145-152
    • Peuskens, J.1    De Hert, M.2    Mortimer, A.3
  • 34
    • 0345293130 scopus 로고    scopus 로고
    • Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: A randomized controlled trial
    • Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290(20):2693-702
    • (2003) JAMA , vol.290 , Issue.20 , pp. 2693-2702
    • Rosenheck, R.1    Perlick, D.2    Bingham, S.3
  • 35
    • 11144354711 scopus 로고    scopus 로고
    • Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone
    • Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry 2004;184:337-45
    • (2004) Br J Psychiatry , vol.184 , pp. 337-345
    • Tohen, M.1    Chengappa, K.N.2    Suppes, T.3
  • 36
    • 0030770872 scopus 로고    scopus 로고
    • Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
    • Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17(5):407-18
    • (1997) J Clin Psychopharmacol , vol.17 , Issue.5 , pp. 407-418
    • Tran, P.V.1    Hamilton, S.H.2    Kuntz, A.J.3
  • 37
    • 28644433423 scopus 로고    scopus 로고
    • Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol
    • Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry 2005;187:537-43
    • (2005) Br J Psychiatry , vol.187 , pp. 537-543
    • Zipursky, R.B.1    Gu, H.2    Green, A.I.3
  • 38
    • 21344437952 scopus 로고    scopus 로고
    • Olanzapine versus lithium in the maintenance treatment of bipolar disorder: A 12-month, randomized, double-blind, controlled clinical trial
    • Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry 2005;162(7):1281-90
    • (2005) Am J Psychiatry , vol.162 , Issue.7 , pp. 1281-1290
    • Tohen, M.1    Greil, W.2    Calabrese, J.R.3
  • 39
    • 33646681652 scopus 로고    scopus 로고
    • A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms
    • Kinon BJ, Lipkovich I, Edwards SB, et al. A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms. J Clin Psychopharmacol 2006;26(2):157-62
    • (2006) J Clin Psychopharmacol , vol.26 , Issue.2 , pp. 157-162
    • Kinon, B.J.1    Lipkovich, I.2    Edwards, S.B.3
  • 40
    • 57049143006 scopus 로고    scopus 로고
    • Patterns of antipsychotic-induced weight change: 3-year results from the intercontinental schizophrenia outpatient-health outcomes (IC-SOHO) study [abstract no. P.3.c.021]
    • Dossenbach M, Pachecho Z, Toledo D, et al. Patterns of antipsychotic-induced weight change: 3-year results from the intercontinental schizophrenia outpatient-health outcomes (IC-SOHO) study [abstract no. P.3.c.021]. Eur Neuropsychopharmacol 2006;16(4 Suppl):S407-8
    • (2006) Eur Neuropsychopharmacol , vol.16 , Issue.4 SUPPL.
    • Dossenbach, M.1    Pachecho, Z.2    Toledo, D.3
  • 41
    • 33846558834 scopus 로고    scopus 로고
    • Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: Observational versus randomized studies results
    • Haro JM, Suarez D, Novick D, et al. Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007;17(4):235-44
    • (2007) Eur Neuropsychopharmacol , vol.17 , Issue.4 , pp. 235-244
    • Haro, J.M.1    Suarez, D.2    Novick, D.3
  • 42
    • 0035108241 scopus 로고    scopus 로고
    • Long-term olanzapine treatment: Weight change and weight-related health factors in schizophrenia
    • Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62(2):92-100
    • (2001) J Clin Psychiatry , vol.62 , Issue.2 , pp. 92-100
    • Kinon, B.J.1    Basson, B.R.2    Gilmore, J.A.3
  • 43
    • 54449091993 scopus 로고    scopus 로고
    • Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed dose study
    • Kinon BJ, Volavka J, Stauffer VL, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, fixed dose study. J Clin Psychopharmacol 2008;28(4):392-400
    • (2008) J Clin Psychopharmacol , vol.28 , Issue.4 , pp. 392-400
    • Kinon, B.J.1    Volavka, J.2    Stauffer, V.L.3
  • 44
    • 33744485015 scopus 로고    scopus 로고
    • Early predictors of substantial weight gain in bipolar patients treated with olanzapine
    • Lipkovich I, Citrome L, Perlis R, et al. Early predictors of substantial weight gain in bipolar patients treated with olanzapine. J Clin Psychopharmacol 2006;26(3):316-20
    • (2006) J Clin Psychopharmacol , vol.26 , Issue.3 , pp. 316-320
    • Lipkovich, I.1    Citrome, L.2    Perlis, R.3
  • 45
    • 46249092841 scopus 로고    scopus 로고
    • Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia
    • Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. Schizophr Res 2008;102(1-3):230-40
    • (2008) Schizophr Res , vol.102 , Issue.1-3 , pp. 230-240
    • Kinon, B.J.1    Chen, L.2    Ascher-Svanum, H.3
  • 46
    • 54049091644 scopus 로고    scopus 로고
    • Schizophrenia, obesity, and antipsychotic medications: What can we do?
    • Citrome L, Vreeland B. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 2008;120(2):18-33
    • (2008) Postgrad Med , vol.120 , Issue.2 , pp. 18-33
    • Citrome, L.1    Vreeland, B.2
  • 47
    • 0035146402 scopus 로고    scopus 로고
    • The continuing increase of diabetes in the US
    • Mokdad AH, Ford ES, Bowman BA, et al. The continuing increase of diabetes in the US. Diabetes Care 2001;24(2):412
    • (2001) Diabetes Care , vol.24 , Issue.2 , pp. 412
    • Mokdad, A.H.1    Ford, E.S.2    Bowman, B.A.3
  • 48
    • 33747024519 scopus 로고    scopus 로고
    • Incidence, prevalence, and surveillance for diabetes in New York State Psychiatric Hospitals, 1997-2004
    • Citrome L, Jaffe A, Levine J, et al. Incidence, prevalence, and surveillance for diabetes in New York State Psychiatric Hospitals, 1997-2004. Psychiatr Serv 2006;57(8):1132-9
    • (2006) Psychiatr Serv , vol.57 , Issue.8 , pp. 1132-1139
    • Citrome, L.1    Jaffe, A.2    Levine, J.3
  • 49
    • 0036020018 scopus 로고    scopus 로고
    • Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use
    • Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70(1):19-26
    • (2002) J Affect Disord , vol.70 , Issue.1 , pp. 19-26
    • Regenold, W.T.1    Thapar, R.K.2    Marano, C.3
  • 50
    • 0027529974 scopus 로고
    • Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth
    • Barker DJ, Hales CN, Fall CH, et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia 1993;36(1):62-7
    • (1993) Diabetologia , vol.36 , Issue.1 , pp. 62-67
    • Barker, D.J.1    Hales, C.N.2    Fall, C.H.3
  • 51
    • 0030021577 scopus 로고    scopus 로고
    • Schizophrenia after prenatal famine. Further evidence
    • Susser E, Neugebauer R, Hoek HW, et al. Schizophrenia after prenatal famine. Further evidence. Arch Gen Psychiatry 1996;53(1):25-31
    • (1996) Arch Gen Psychiatry , vol.53 , Issue.1 , pp. 25-31
    • Susser, E.1    Neugebauer, R.2    Hoek, H.W.3
  • 52
    • 0032977072 scopus 로고    scopus 로고
    • The unhealthy lifestyle of people with schizophrenia
    • Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29(3):697-701
    • (1999) Psychol Med , vol.29 , Issue.3 , pp. 697-701
    • Brown, S.1    Birtwistle, J.2    Roe, L.3
  • 53
    • 33646103388 scopus 로고    scopus 로고
    • Clustering of metabolic comorbidity in schizophrenia: A genetic contribution?
    • Gough SC, O'Donovan MC. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution? J Psychopharmacol 2005;19(6 Suppl):47-55
    • (2005) J Psychopharmacol , vol.19 , Issue.6 SUPPL. , pp. 47-55
    • Gough, S.C.1    O'Donovan, M.C.2
  • 54
    • 37049000576 scopus 로고    scopus 로고
    • Blood glucose and schizophrenia: A systematic review of prospective randomized clinical trials
    • Bushe CJ, Leonard BE. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. J Clin Psychiatry 2007;68(11):1682-90
    • (2007) J Clin Psychiatry , vol.68 , Issue.11 , pp. 1682-1690
    • Bushe, C.J.1    Leonard, B.E.2
  • 55
    • 0037315939 scopus 로고    scopus 로고
    • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics
    • Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160(2):290-6
    • (2003) Am J Psychiatry , vol.160 , Issue.2 , pp. 290-296
    • Lindenmayer, J.P.1    Czobor, P.2    Volavka, J.3
  • 56
    • 4744338410 scopus 로고    scopus 로고
    • Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder
    • Simpson GM, Glick ID, Weiden PJ, et al. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004;161(10):1837-47
    • (2004) Am J Psychiatry , vol.161 , Issue.10 , pp. 1837-1847
    • Simpson, G.M.1    Glick, I.D.2    Weiden, P.J.3
  • 57
    • 23344434378 scopus 로고    scopus 로고
    • Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia
    • Simpson GM, Weiden P, Pigott T, et al. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Am J Psychiatry 2005;162(8):1535-8
    • (2005) Am J Psychiatry , vol.162 , Issue.8 , pp. 1535-1538
    • Simpson, G.M.1    Weiden, P.2    Pigott, T.3
  • 58
    • 33750026127 scopus 로고    scopus 로고
    • Metabolic changes during 5 months treatment with olanzapine or risperidone: Preliminary results from randomized trial [abstract]
    • Smith RC, lindenmayer A, Buga A, et al. Metabolic changes during 5 months treatment with olanzapine or risperidone: preliminary results from randomized trial [abstract]. Schizophr Bull 2005;31(2):570
    • (2005) Schizophr Bull , vol.31 , Issue.2 , pp. 570
    • Smith, R.C.1    lindenmayer, A.2    Buga, A.3
  • 59
    • 33744964843 scopus 로고    scopus 로고
    • Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia
    • Wu RR, Zhao JP, Liu ZN, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology 2006;186(4):572-8
    • (2006) Psychopharmacology , vol.186 , Issue.4 , pp. 572-578
    • Wu, R.R.1    Zhao, J.P.2    Liu, Z.N.3
  • 60
    • 0344033647 scopus 로고    scopus 로고
    • A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse
    • Beasley CMJ, Sutton VK, Hamilton SH, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. J Clin Psychopharmacol 2003;23(6):582-94
    • (2003) J Clin Psychopharmacol , vol.23 , Issue.6 , pp. 582-594
    • Beasley, C.M.J.1    Sutton, V.K.2    Hamilton, S.H.3
  • 61
    • 34748881146 scopus 로고    scopus 로고
    • Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics
    • Chrome L, Holt RI, Zachry WM, et al. Risk of treatment-emergent diabetes mellitus in patients receiving antipsychotics. Ann Pharmacother 2007;41(10):1593-603
    • (2007) Ann Pharmacother , vol.41 , Issue.10 , pp. 1593-1603
    • Chrome, L.1    Holt, R.I.2    Zachry, W.M.3
  • 62
    • 33748749787 scopus 로고    scopus 로고
    • The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients
    • Chiu CC, Chen KP, Liu HC, et al. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol 2006;26(5):504-7
    • (2006) J Clin Psychopharmacol , vol.26 , Issue.5 , pp. 504-507
    • Chiu, C.C.1    Chen, K.P.2    Liu, H.C.3
  • 63
    • 0036001466 scopus 로고    scopus 로고
    • Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 published cases
    • Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14(1):59-64
    • (2002) Ann Clin Psychiatry , vol.14 , Issue.1 , pp. 59-64
    • Jin, H.1    Meyer, J.M.2    Jeste, D.V.3
  • 64
    • 33746123940 scopus 로고    scopus 로고
    • Do guidelines for severe mental illness promote physical health and well-being?
    • Citrome L, Yeomans D. Do guidelines for severe mental illness promote physical health and well-being? J Psychopharmacol 2005;19(6 Suppl):102-9
    • (2005) J Psychopharmacol , vol.19 , Issue.6 SUPPL. , pp. 102-109
    • Citrome, L.1    Yeomans, D.2
  • 65
    • 0037798919 scopus 로고    scopus 로고
    • Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics
    • Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64(5):598-4
    • (2003) J Clin Psychiatry , vol.64 , Issue.5 , pp. 598-604
    • Atmaca, M.1    Kuloglu, M.2    Tezcan, E.3
  • 66
    • 0035002177 scopus 로고    scopus 로고
    • A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder
    • Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 2001;158(5):765-74
    • (2001) Am J Psychiatry , vol.158 , Issue.5 , pp. 765-774
    • Conley, R.R.1    Mahmoud, R.2
  • 67
    • 35948939626 scopus 로고    scopus 로고
    • Olanzapine: Interpreting the label change
    • Citrome L. Olanzapine: interpreting the label change. Int J Clin Pract 2007;61(12):1960-2
    • (2007) Int J Clin Pract , vol.61 , Issue.12 , pp. 1960-1962
    • Citrome, L.1
  • 68
    • 42149146835 scopus 로고    scopus 로고
    • Interpreting and applying the EUFEST results using number needed to treat: Antipsychotic effectiveness in first-episode schizophrenia
    • Citrome L. Interpreting and applying the EUFEST results using number needed to treat: antipsychotic effectiveness in first-episode schizophrenia. Int J Clin Pract 2008;62(5):837-40
    • (2008) Int J Clin Pract , vol.62 , Issue.5 , pp. 837-840
    • Citrome, L.1
  • 69
    • 33947430212 scopus 로고    scopus 로고
    • Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: A population-based Study
    • Yang S-Y, Kao Yang Y-H, Chong M-Y, et al. Risk of extrapyramidal syndrome in schizophrenic patients treated with antipsychotics: a population-based Study. Clin Pharmacol Ther 2007;81(4):586-94
    • (2007) Clin Pharmacol Ther , vol.81 , Issue.4 , pp. 586-594
    • Yang, S.-Y.1    Kao Yang, Y.-H.2    Chong, M.-Y.3
  • 70
    • 40949136198 scopus 로고    scopus 로고
    • Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: A systematic review
    • Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008;28(2):203-9
    • (2008) J Clin Psychopharmacol , vol.28 , Issue.2 , pp. 203-209
    • Gao, K.1    Kemp, D.E.2    Ganocy, S.J.3
  • 71
    • 40349094467 scopus 로고    scopus 로고
    • Tardive dyskinesia and new antipsychotics
    • Correll, CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21(2):151-6
    • (2008) Curr Opin Psychiatry , vol.21 , Issue.2 , pp. 151-156
    • Correll, C.U.1    Schenk, E.M.2
  • 72
    • 26644456940 scopus 로고    scopus 로고
    • Effects of antipsychotic treatment on tardive dyskinesia: A 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study
    • Tenback DE, van Harten PN, Slooff CJ, et al. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiatry 2005;66(9):1130-3
    • (2005) J Clin Psychiatry , vol.66 , Issue.9 , pp. 1130-1133
    • Tenback, D.E.1    van Harten, P.N.2    Slooff, C.J.3
  • 73
    • 25144482343 scopus 로고    scopus 로고
    • Antipsychotic medications and drug-induced movement disorders other than parkinsonism: A population-based cohort study in older adults
    • Lee PE, Sykora K, Gill SS, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc 2005;53(8):1374-9
    • (2005) J Am Geriatr Soc , vol.53 , Issue.8 , pp. 1374-1379
    • Lee, P.E.1    Sykora, K.2    Gill, S.S.3
  • 74
    • 37849006140 scopus 로고    scopus 로고
    • Tardive dyskinesia: Minimizing risk and improving outcomes in schizophrenia and other disorders
    • Citrome L, Dufresne R, Dyrud JM. Tardive dyskinesia: minimizing risk and improving outcomes in schizophrenia and other disorders. Am J Manag Care 2007;13(Suppl):1-12
    • (2007) Am J Manag Care , vol.13 , Issue.SUPPL. , pp. 1-12
    • Citrome, L.1    Dufresne, R.2    Dyrud, J.M.3
  • 75
    • 37849034195 scopus 로고    scopus 로고
    • Differences in the effect of second-generation antipsychotics on prolactinaemia: Six weeks open-label trial in female in-patients
    • Svestka J, Synek O, Tomanová J, et al. Differences in the effect of second-generation antipsychotics on prolactinaemia: six weeks open-label trial in female in-patients. Neuro Endocrinol Lett 2007; 28(6):881-8
    • (2007) Neuro Endocrinol Lett , vol.28 , Issue.6 , pp. 881-888
    • Svestka, J.1    Synek, O.2    Tomanová, J.3
  • 76
    • 51149107891 scopus 로고    scopus 로고
    • A review of the association between antipsychotic use and hyperprolactinaemia
    • Bushe C, Shaw M, Peveler RC. A review of the association between antipsychotic use and hyperprolactinaemia. J Clin Psychopharmacol 2008;22(2 Suppl):46-55
    • (2008) J Clin Psychopharmacol , vol.22 , Issue.2 SUPPL. , pp. 46-55
    • Bushe, C.1    Shaw, M.2    Peveler, R.C.3
  • 77
    • 1442357994 scopus 로고    scopus 로고
    • Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol
    • Volavka J, Czobor P, Cooper TB, et al. Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. J Clin Psychiatry 2004;65(1):57-61
    • (2004) J Clin Psychiatry , vol.65 , Issue.1 , pp. 57-61
    • Volavka, J.1    Czobor, P.2    Cooper, T.B.3
  • 78
    • 51149117634 scopus 로고    scopus 로고
    • Current guidelines and their recommendations for prolactin monitoring in psychosis
    • Citrome L. Current guidelines and their recommendations for prolactin monitoring in psychosis. J Psychopharmacol 2007;22(2 Suppl):90-7
    • (2007) J Psychopharmacol , vol.22 , Issue.2 SUPPL. , pp. 90-97
    • Citrome, L.1
  • 79
    • 0029066856 scopus 로고
    • Diabetes, psychological function and male sexuality
    • Schiavi RC, Stimmel BB, Mandeli J, et al. Diabetes, psychological function and male sexuality. J Psychosom Res 1995;39(3):305-14
    • (1995) J Psychosom Res , vol.39 , Issue.3 , pp. 305-314
    • Schiavi, R.C.1    Stimmel, B.B.2    Mandeli, J.3
  • 80
    • 0028135281 scopus 로고
    • Psychotropic medications and their effects on sexual function: Diagnosis, biology, and treatment approaches
    • Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994;55(9):406-13
    • (1994) J Clin Psychiatry , vol.55 , Issue.9 , pp. 406-413
    • Gitlin, M.J.1
  • 81
    • 51149117097 scopus 로고    scopus 로고
    • Understanding osteoporosis
    • Javaid MK, Holt RIG. Understanding osteoporosis. J Psychopharmacol 2008;22(2 Suppl):38-45
    • (2008) J Psychopharmacol , vol.22 , Issue.2 SUPPL. , pp. 38-45
    • Javaid, M.K.1    Holt, R.I.G.2
  • 82
    • 51149115350 scopus 로고    scopus 로고
    • Antipsychotics and hyperprolactinaemia: Clinical recommendations
    • Peveler RC, Branford D, Citrome L, et al. Antipsychotics and hyperprolactinaemia: clinical recommendations. J Psychopharmacol 2008;22(2 Suppl):98-103
    • (2008) J Psychopharmacol , vol.22 , Issue.2 SUPPL. , pp. 98-103
    • Peveler, R.C.1    Branford, D.2    Citrome, L.3
  • 83
    • 44849105921 scopus 로고    scopus 로고
    • Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia
    • Goder R, Fritzer G, Gottwald B, et al. Effects of olanzapine on slow wave sleep, sleep spindles and sleep-related memory consolidation in schizophrenia. Pharmacopsychiatry 2008;41(3):92-9
    • (2008) Pharmacopsychiatry , vol.41 , Issue.3 , pp. 92-99
    • Goder, R.1    Fritzer, G.2    Gottwald, B.3
  • 84
    • 41549116886 scopus 로고    scopus 로고
    • A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: Focus on somnolence
    • Gao K, Ganocy SJ, Gajwani P, et al. A review of sensitivity and tolerability of antipsychotics in patients with bipolar disorder or schizophrenia: focus on somnolence. J Clin Psychiatry 2008;69(2):302-9
    • (2008) J Clin Psychiatry , vol.69 , Issue.2 , pp. 302-309
    • Gao, K.1    Ganocy, S.J.2    Gajwani, P.3
  • 85
    • 35148822313 scopus 로고    scopus 로고
    • Atypical antipsychotics, elderly patients, and moraity risk
    • Citrome L. Atypical antipsychotics, elderly patients, and moraity risk. South Med J 2007;100(1):964-5
    • (2007) South Med J , vol.100 , Issue.1 , pp. 964-965
    • Citrome, L.1
  • 87
    • 0141842769 scopus 로고    scopus 로고
    • Antipsychocic medication and seizures: A review
    • Hedges D, Jeppson K, Whitehead P. Antipsychocic medication and seizures: a review. Drugs Today 2003;39(7):551-7
    • (2003) Drugs Today , vol.39 , Issue.7 , pp. 551-557
    • Hedges, D.1    Jeppson, K.2    Whitehead, P.3
  • 88
    • 0038715822 scopus 로고    scopus 로고
    • Olanzapine induced neuroleptic malignant syndrome - a case review
    • Kogoj A, Velikonja I. Olanzapine induced neuroleptic malignant syndrome - a case review. Hum Psychopharmacol 2003;18(4):301-9
    • (2003) Hum Psychopharmacol , vol.18 , Issue.4 , pp. 301-309
    • Kogoj, A.1    Velikonja, I.2
  • 89
    • 33746771436 scopus 로고    scopus 로고
    • Olanzapine-Associated Neuroleptic Malignant Syndrome
    • Norgard NB, Stark JE. Olanzapine-Associated Neuroleptic Malignant Syndrome. Pharmacotherapy 2006;26(8):1180-2
    • (2006) Pharmacotherapy , vol.26 , Issue.8 , pp. 1180-1182
    • Norgard, N.B.1    Stark, J.E.2
  • 91
    • 0141790782 scopus 로고    scopus 로고
    • A review of olanzapine-associated toxicity and fatality in overdose
    • Chue P, Singer P. A review of olanzapine-associated toxicity and fatality in overdose. J Psychiatry Neurosci 2003;28(4):253-61
    • (2003) J Psychiatry Neurosci , vol.28 , Issue.4 , pp. 253-261
    • Chue, P.1    Singer, P.2
  • 92
    • 46949084286 scopus 로고    scopus 로고
    • Using antipsychotics for the treatment of schizophrenia: Likelihood to be helped or harmed, understanding proximal and distal benefits and risks
    • Citrome L, Kantrowitz J. Using antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008;8(7):1079-91
    • (2008) Expert Rev Neurother , vol.8 , Issue.7 , pp. 1079-1091
    • Citrome, L.1    Kantrowitz, J.2
  • 93
    • 33746115248 scopus 로고    scopus 로고
    • Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: How can CATIE inform clinicians?
    • Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60(8):933-40
    • (2006) Int J Clin Pract , vol.60 , Issue.8 , pp. 933-940
    • Citrome, L.1    Stroup, T.S.2
  • 94
    • 48949120897 scopus 로고    scopus 로고
    • Reporting outcomes in clinical trials for bipolar disorder: A commentary and suggestions for change
    • Martinez-Arán A, Vieta E, Chengappa KN, et al. Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change. Bipolar Disord 2008;10(5):566-79
    • (2008) Bipolar Disord , vol.10 , Issue.5 , pp. 566-579
    • Martinez-Arán, A.1    Vieta, E.2    Chengappa, K.N.3
  • 95
    • 35648936485 scopus 로고    scopus 로고
    • Reviewing CATIE for clinicians: Balancing benefit and risk using evidence-based medicine tools
    • Karagianis J, Rosenbluth M, Tohen M, et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23(10):2551-7
    • (2007) Curr Med Res Opin , vol.23 , Issue.10 , pp. 2551-2557
    • Karagianis, J.1    Rosenbluth, M.2    Tohen, M.3
  • 96
    • 57049091477 scopus 로고    scopus 로고
    • Berenson A. Eli Lilly Said to Play Down Risk of Top Pill. New York Times. December 17, 2006. Available from: http://www.nytimes.com/2006/12/ 17/business/17drug.html [Last accessed 2008 Sept 3]
    • Berenson A. Eli Lilly Said to Play Down Risk of Top Pill. New York Times. December 17, 2006. Available from: http://www.nytimes.com/2006/12/ 17/business/17drug.html [Last accessed 2008 Sept 3]
  • 97
    • 34948858402 scopus 로고    scopus 로고
    • Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized Phase 2 clinical trial
    • Patil ST, Zhang L, Martenyi F, et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007;13(9):1102-7
    • (2007) Nat Med , vol.13 , Issue.9 , pp. 1102-1107
    • Patil, S.T.1    Zhang, L.2    Martenyi, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.